Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
Pharmaceutical Technology22h
Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...
Hong Kong Stock Market May Stop The Bleeding On Friday
The Hong Kong stock market has finished lower in four straight sessions, retreating more than 520 points or 2.8 percent along the ...
The Biopharmaceutical Contract Manufacturing Market to Hit $38.07 Billion by 2029, Revenue to Double in the Next 6 Years – Arizton
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
Dundalk Democrat15h
Wuxi employees make generous donation to St Vincent De Paul Dundalk
WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...
The Pharmaceutical R&D Outsourcing Market on Track for $150 Billion Milestone, North America Takes the Spotlight – Arizton
Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...